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Protocol digest of JCOG1401
Objectives
The aim of this trial is to demonstrate the safety of LATG and LAPG with nodal dissection for patients with clinical stage I gastric cancer.
Study setting
This is a multi-institutional non-randomized confirmatory trial.
Endpoints
The primary endpoint is the proportion of patients with 
Eligibility criteria
Gastric cancer is staged according to the Japanese Classification of Gastric Carcinoma -14th Japanese version, which corresponds to the 3rd English edition. 2) Infectious disease with systemic therapy indicated.
3) Body temperature of ≥38 degrees Celsius. 
Registration
After confirming fulfillment of the eligibility criteria, registration is performed using the web-based system of the JCOG Data Center.
Treatment methods
LATG or LAPG will be performed. The extent of nodal dis- 
Quality control of surgery 1) Certified surgeon for laparoscopic gastrectomy
All of the following criteria (1)~(3) of a certified surgeon must be fulfilled.
(1) Experience of performing 30 or more laparoscopic gastrectomies.
(2) Certification in the area of gastric cancer by either a surgical quality assurance (QA) committee or the Japan Society for Endoscopic Surgery. 
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teaching assistant.
Intraoperative photographs and video recording
A surgical QA committee performs central peer review of the surgical procedure by photographing all patients. Central peer review is performed every 6 to 12 months. Intraoperative video of arbitrarily selected patients is also shown in a group conference that is held 3 times a year to share the operation procedure.
Follow-up
All registered patients will be followed up for at least 5 years without any adjuvant chemotherapy, except for the patients who are finally diagnosed with pathological stage II, IIIA, or IIIB.
Adjuvant chemotherapy with S-1 for 1 year is recommended for these patients. Tumor markers, chest radiography, upper gastrointestinal endoscopy, and enhanced abdominal computed tomography will be evaluated at least every year and for at least 5 years. Previous large-scale studies reported that the proportion of patients with esophagojejunal anastomotic leakage was 2% to 3% when open total or proximal gastrectomy was performed. 9, 10 Similarly, when LATG or LAPG was performed, the proportion of patients with esophagojejunal anastomotic leakage was reported to be 0% to 4% according to available retrospective data. [11] [12] [13] [14] Taking these reports into account, the sample size was calculated as 242 patients in order to provide 90% power, with the hypothesis that the primary endpoint would have an expected value of 3% and threshold value of 8%, using one-sided testing at a 2.5% significance level. The total sample size was set at 245 patients by assuming that a few patients will not undergo gastrectomy. The Kaplan-Meier method will be used for analysis of overall survival or relapse-free survival. All statistical analyses will be conducted at the JCOG Data Center.
Study design and statistical analysis

Interim analysis and monitoring
Interim analysis is not planned. When treatment-related death or severe (grade 4) surgical morbidity is observed in 8 or more patients, the registration will be suspended and the JCOG Data and Safety Monitoring Committee will determine whether the trial can restart.
In-house interim monitoring will be performed every 6 months by the JCOG Data Center to evaluate and improve study progress, data integrity, and patient safety.
Participating institutions
